Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma
Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been...
View ArticleJanssen granted Priority Review from FDA for YONDELIS (trabectedin) NDA to...
Janssen Research & Development, LLC announced today that the U.S. Food and Drug Administration has granted Priority Review for the New Drug Application (NDA) for YONDELIS (trabectedin) to treat...
View ArticleCombination of anti-Nodal and DTIC therapy can produce anti-cancer effects
Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened.
View ArticleArray BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015...
Array BioPharma Inc. today announced presentations on encorafenib, binimetinib and selumetinib (licensed to AstraZeneca) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which...
View ArticleEisai Phase 3 trial of eribulin meets primary endpoint in patients with...
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced...
View ArticleTrabectedin may be better than dacarbazine for treatment of soft tissue sarcoma
Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®)...
View ArticlePhase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients...
AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of...
View ArticleArray Biopharma reports strong fourth quarter and full year 2015 financial...
Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
View ArticleFDA approves Yondelis (trabectedin) for treatment of specific soft tissue...
The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be...
View ArticleArray BioPharma reports top-line results from binimetinib Phase 3 trial in...
Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary...
View ArticleHalaven (eribulin mesylate) approved for treatment of liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be...
View ArticleEisai's Halaven receives FDA approval for treatment of patients with...
Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic...
View ArticleExperts to analyse latest advances in diagnosis, treatment of soft tissue...
The creation of a network of centres of reference and adopting measures that promote research and access to treatments are two key aspects for improving the prognosis of patients with soft tissue...
View ArticleChemotherapy drug combination appears to increase production of eggs in...
Women treated with a common chemotherapy drug combination have more young eggs in their ovaries afterwards, research has found.
View ArticleStudy addresses cost-effectiveness of checkpoint inhibitors for advanced...
Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.
View ArticlePhase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients...
AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of...
View ArticleArray Biopharma reports strong fourth quarter and full year 2015 financial...
Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.
View ArticleFDA approves Yondelis (trabectedin) for treatment of specific soft tissue...
The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be...
View ArticleArray BioPharma reports top-line results from binimetinib Phase 3 trial in...
Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary...
View ArticleHalaven (eribulin mesylate) approved for treatment of liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be...
View Article
